First Commercial Installation Targeted for July 2026 in San Antonio; Strategic Reference Site Positions Velocity Bioworks at the Forefront of Next-Generation NMR-Based Diagnostics

Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) (Nasdaq: VBIO), a clinical-stage immunotherapeutics company, announced that its wholly owned subsidiary, Velocity Bioworks, has entered into an exclusive commercial development and license agreement with LarmorBio, Inc. ("LarmorBio") for LarmorBio's BioScan-NMR™ platform, a next-generation nuclear magnetic resonance (NMR) system. Under the agreement, Velocity Bioworks will host the first commercial deployment of the BioScan-NMR platform, with installation and commissioning at the Company's San Antonio facility targeted for July 2026.

Valion Bio secured the exclusive license and reference site arrangement at pre-institutional pricing, ahead of LarmorBio's pending Series A financing. The structure aligns the two companies as co-dependent strategic partners — rather than in a conventional vendor-customer relationship — with both parties commercially and operationally aligned on the validation, optimization, and scaled deployment of the BioScan-NMR platform.

"Securing exclusive commercial rights to BioScan-NMR ahead of LarmorBio's Series A reflects how we are building Velocity Bioworks — early access to differentiated technologies, structural alignment with the developer, and a position that strengthens as the platform scales," said Michael K. Handley, Chief Executive Officer of Valion Bio. "Hosting the first commercial installation gives Velocity Bioworks a defined role in the validation and commercialization of a next-generation NMR platform, and supports an advanced diagnostics service offering that we believe will benefit the biomanufacturing of programs both our internal pipeline and our third-party CDMO clients."

The San Antonio installation, targeted for commissioning in July 2026, is expected to anchor Velocity Bioworks' advanced diagnostics service offering and to serve as the demonstration and validation site for LarmorBio's broader commercial pipeline. The reference site role provides Velocity Bioworks with first-mover access to the platform, while giving LarmorBio a high-visibility commercial proof point as it engages institutional capital and prospective customers.